Summary

Original source:
http://www.iht.com/articles/2005/11/21/business/hot.php

Details

• MONDAY, NOVEMBER 21, 2005 LONDON Shares in GlaxoSmithKline fell more than 4 percent on Monday after the U.S. Food and Drug and Administration proposed restrictions on the use of Advair, the British pharmaceutical maker's top-selling asthma drug.
• The drug agency said on Friday that Advair, which is sold in Europe under the name Seretide, should not be given as initial treatment for asthma but only after other medicines had proved inefficient.
• The move by the FDA followed the release of results from a clinical study that showed that drugs that contain long-acting beta agonists, or LABAs, can sometimes trigger severe asthma attacks and death.
• It revised its U.S. sales expectations for Advair to £2.24 billion, or $3.85 billion, by 2010, down from a previous forecast of £2.93 billion.
• Worldwide sales of Advair totaled £3.43 billion last year, making it Glaxo's best-selling product.
• Glaxo has been counting on Advair to drive its business in the next few years, until some of its experimental drugs have proved themselves in clinical trials and reached the market.
• Analysts at Morgan Stanley said that more than 25 percent of Advair use in the United States fell under the definition of initial use, rather than after other drugs showed themselves to be ineffectual.
• Current U.S. guidelines recommend steroids and LABAs as initial therapy for moderate to severe-persistent asthma.
• The new FDA warnings also will affect drugs like Serevent, the LABA component of Advair used by Glaxo, which the company also sells as a separate drug.
• They are also expected to affect Foradil, which is made by Novartis.
• Drugs like Singulair, an oral treatment made by Merck, and Asmanex, a long-acting inhaled steroid by Schering-Plough, are among those who could see their market share increase.

Related Articles

Popular Topics: GlaxoSmithKline, Asthma, The FDA, Diabetes, Breast cancer, Prostate cancer, Heart disease, Depression, High cholesterol, Osteoporosis, Vaccines, Autism, ADHD, Infertility, Weight loss, Cancer, Alzheimer's, Trans fats, Acrylamides, Fluoride, Mercury	Take Action: Support NaturalNews.com Email this article to a friend Share this article on: NewsVine | digg | del.icio.us Permalink to this article: http://www.NaturalNews.com/015433.html Reprinting this article: Non-commercial OK, cite NaturalNews.com with clickable link. <a href = "http://www.NaturalNews.com/015433.html">FDA restrictions on Advair impacts GlaxoSmithKline shares</a>
Receive our Natural Health Newsletter for FREE Subscribe now (it's free!) to win. We randomly choose a subscriber each month to send $100 in eco-home products or a RealGoods.com gift certificate (our choice). Plus, you'll receive FREE news, articles and action alerts from NaturalNews.com editors and join over 800,000 monthly readers who report extraordinary health improvements after becoming a subscriber! Receive breaking news alerts on natural health solutions, renewable energy, the environment, global warming and more. Receive a free instant download of our $29 Secret Sources guide that reveals top sources for little-known health and diet solutions.	Your Email Address: Free Subscription Code: Enter the numbers you see: 100% free of charge. Unsubscribe anytime. Absolutely no spam. We respect your email privacy.
Recommended Special Report: Seven Words that can Change the World by Joseph R. Simonetta Read this special report now... "Seven Words That Can Change the World reveals the astonishing, simple truths that have the power to forever transform our world for the better while freeing our minds from the enslavement of limiting beliefs. This is not a text for the simple-minded; it is a guiding philosophy for the mindful, intelligent few who are wise enough to seek out -- and recognize -- the higher simplicities of truly purposeful living." - Mike Adams, the Health Ranger, editor of NaturalNews.com	More on NaturalNews.com: • Streaming Health Ranger Videos • CounterThink Cartoons • FREE Special Reports • Podcasts